neuroendocrine prostate cancer

Deadly Subtype Makes Up 17% of Metastatic Prostate Cancers Bookmark

Excerpt from Healio:

“Treatment-emergent small cell neuroendocrine prostate cancer, a particularly deadly subtype of the disease, occurs in nearly one-fifth of all cases of metastatic, castration-resistant prostate cancer, study data showed.

“Researchers suggested that the subtype should be treated with novel targeted therapies that are currently in the development or testing phase.”

Go to full article published by Healio on July 9, 2018.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.